Monitor the level of HLA-DR of peripheral blood CD14+monocyte dynamically to predict the prognosis of patients with severe pneumonia
Zhuxi Yu,Xiancheng Chen,Beiyuan Zhang,HaoYingying,Danjiang Dong,Qin Gu
DOI: https://doi.org/10.3877/cma.j.issn.1674-6902.2018.03.005
2018-01-01
Abstract:Objective To investigate the relationship between Human leukocyte DR antigen level, change trend and prognosis of patients with severe pneumonia.Methods A retrospective analysis of 36 patients with severe pneumonia admitted in our hospital from 2015 to 2017, according to survival within 28 days after admission divide into two groups, death group of 16cases, and survival group of 20 cases. Monitor the level of Human leukocyte DR antigen in patients in Day1, Day3, Day7 and to compare the relationship with the level of Human leukocyte DR antigen and the prognosis of patients. Results Comparison of the Human leukocyte DR antigen, in D1 Human leukocyte DR antigen, survival group was 29.3±9.0, death group was 59.6±17.4, P<0.001. D3 Human leukocyte DR antigen, survival group was 50.3±18.6, death group was 57.0±21.9, P>0.05. D7 Human leukocyte DR antigen, survival group was 41.6± 21.0, death group was 27.8± 11.8, P<0.05. Δ1 (D3-D1), survival group was 21.0±22.2, death group was -2.6±24.8, P<0.05. Δ2(D7-D1), survival group was 12.3±28.6,death group was -30.4±28.7, P<0.001. Δ3(D7-D3), survival group was -8.7±13.7, death group was -29.2 ± 13.1, P<0.001. Conclusions Monitor the level of Human leukocyte DR antigen of peripheral blood CD14+monocyte dynamically can help determine the prognosis of patients with severe pneumonia.